Migraine sufferers left devastated after being denied ground-breaking drug on NHS which ‘prevents half of attacks’

MIGRAINE sufferers have been left devastated after being denied a ground-breaking drug on the NHS.

Erenumab, the first new treatment in 20 years, prevents nearly half of attacks in those hardest hit.

Up to 100,000 Brits with chronic migraines could have potentially benefited from the drug
Getty – Contributor

In draft guidance, watchdog the National Institute for Health and Care Excellence said it was promising but ruled that it is was not cost-effective. It also said there was not enough proof it was better than current treatment Botox.

Erenumab — developed by Dr Peter Goadsby, Professor of Neurology at King’s College London — costs around £5,000 a year, though the NHS would get it at a discount.

Experts estimate the drug would have helped 100,000 chronic cases. Wendy Thomas, of The Migraine Trust, said: “This is devastating for people whose lives are blighted. After proving effective to many, it is not accessible.”

The monthly self-administered jab works by blocking pain signals that trigger the crippling headaches.

Dr David Bloomfield, head of the National Migraine Centre, said: “We are disappointed.”

  • GRANDAD Barrington Simner, 72, is the first Brit migraine sufferer cured with “zaps” from a device that delivers single pulse Transcranial Magnetic Stimulation at Guy’s and St Thomas’ Hospital, South London.


(Visited 31 times, 1 visits today)

Leave a Reply